Clinical trials: Disability Physical
Multiple Sclerosis
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS).
- Trial name
- TEMSO (NCT00134563)
- Testing
- Teriflunomide
- Where
- 21 sites in United States, Austria and 19 more
- Volunteers
- 1,088 people
- Sponsor
- Sanofi
Prader-Willi Syndrome
PWS Outcomes Assessment Study
This is a longitudinal study during which qualitative interviews will be conducted with caregivers of Soleno C601/C602 study subjects.
- Trial name
- NCT04102839
- Testing
- Interview
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Soleno Therapeutics, Inc.
Severe Knee Pain, Severe Knee Disability
Zimmer POLAR Persona - TKA (EMEA Study)
The primary objective of this study is to obtain implant survivorship and clinical outcomes data for commercially available Persona knee implants used in primary total knee arthroplasty. The assessment will include: 1.
- Conditions
- Severe Knee Pain, Severe Knee Disability, Osteoarthritis, Rheumatoid Arthritis
- Trial name
- NCT02337244
- Testing
- Zimmer Persona Total Knee System
- Where
- 12 sites in Austria, France and 4 more
- Volunteers
- 777 people
- Sponsor
- Zimmer, GmbH
Down Syndrome, Edwards Syndrome
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
In January 2007, the American Congress of Obstetricians and Gynecologists (ACOG) revised its guidelines that now recommend physicians are ethically obligated to fully inform all pregnant women that screening for fetal chromosomal…
- Conditions
- Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome
- Trial name
- NCT02787486
- Testing
- Blood sampling for Laboratory Developed Test (LDT) analysis
- Where
- 8 sites in United States
- Volunteers
- 760 people
- Sponsor
- Progenity, Inc.
Multiple Sclerosis
The MS-LINK™ Outcomes Study
The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes.
- Trial name
- NCT04735406
- Where
- 9 sites in United States
- Volunteers
- 2,182 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Chronic Physical Health Conditions
MANAGE AT WORK: Addressing the Challenge of Chronic Physical Health Conditions in the Workplace
The specific aim of the study is to evaluate the health benefits of a series of group workshops designed for workers with chronic physical health conditions.
- Trial name
- NCT01978392
- Testing
- Self-management group workshops
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- Liberty Mutual Research Institute for Safety
Multiple Sclerosis, Relapsing-Remitting
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
The Canadian Multiple Sclerosis Working Group (CMSWG) has developed practical recommendations on how neurologists can assess the status of subjects on disease modifying drugs (DMDs) and decide when it may be necessary to modify…
- Trial name
- CanTOR (NCT01142583)
- Volunteers
- 192 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Autism Spectrum Disorder, Autism
Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD)
The goal of this clinical study is to learn about the utility and performance of the EarliPoint System (™): Evaluation for Autism Spectrum Disorder to diagnose and assess autism spectrum disorder (ASD) in children ages 31-96…
- Trial name
- MEASURE-ASD2 (NCT05806216)
- Testing
- EarliPoint Diagnosis, Clinically Certain Expert Clinician Diagnosis (CC-ECD)
- Where
- 9 sites in United States
- Volunteers
- 929 people, healthy volunteers welcome
- Sponsor
- EarliTec Diagnostics, Inc
Neurodevelopmental Disorders, Autism Spectrum Disorder
A Game-based Neurodevelopmental Assessment for Young Children
The aim of this study is to evaluate a novel tablet game-based neurodevelopmental assessment tool for young children aged 3 to 8 years old.
- Conditions
- Neurodevelopmental Disorders, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Dyslexia
- Trial name
- BRIGHTEN (NCT05780853)
- Testing
- Tablet Game-based Assessment - YARN assessment service, Adaptive Behavior Assessment System, Third Edition (ABAS-3), Demographic questionnaire
- Where
- United Kingdom
- Volunteers
- 590 people, healthy volunteers welcome
- Sponsor
- Brightlobe Limited